Literature DB >> 6366093

Identification of a thermolysin-like metalloendopeptidase in serum: activity in normal subjects and in patients with sarcoidosis.

J Almenoff, A S Teirstein, J C Thornton, M Orlowski.   

Abstract

A thermolysin-like metalloendopeptidase, optimally active at a neutral pH, was identified in human serum. The enzyme cleaves the synthetic substrate glutaryl-Ala-Ala-Phe-2-naphthylamide at the Ala-Phe bond. Activity was determined by measuring the rate of formation of Phe-2-naphthylamide in a coupled enzyme assay in the presence of excess aminopeptidase M. 2-Naphthylamine released during the reaction was determined by a diazotization procedure. Enzyme activity is not affected by inhibitors of serine, thiol, or carboxyl proteases, but is sensitive to inhibition by metal chelators such as EDTA and o-phenanthroline. Dialysis against EDTA leads to loss of activity, which can be fully restored by zinc and cobalt ions. The serum enzyme closely resembles a membrane-bound metalloendopeptidase (EC 3.4.24.11) abundant in lung, spleen, and kidney in that both enzymes are inhibited by the same active-site-directed inhibitors. In addition, an antiserum obtained against the metalloendopeptidase from rabbit kidney shows strong cross-reactivity with the serum enzyme. Metalloendopeptidase activity was measured in 150 controls and in 95 patients with sarcoidosis; the two groups had significantly different enzyme activities (p less than 0.001). The mean enzyme activity in the sarcoidosis group was more than threefold higher than that of the control group. The mean enzyme activity for patients with active disease was more than double that of patients with inactive disease and more than four times that of controls (p less than 0.001). This is noteworthy because angiotensin converting enzyme, a zinc-dipeptidyl carboxypeptidase with a mechanism of action similar to that of the metalloendopeptidase, has also been reported to be increased in the serum of patients with active sarcoidosis. Enzyme activity in patients with active tuberculosis, primary pulmonary neoplasms, and idiopathic interstitial pulmonary fibrosis did not differ significantly from that of controls.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6366093

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  6 in total

1.  Molecular cloning and biochemical characterization of a new mouse testis soluble-zinc-metallopeptidase of the neprilysin family.

Authors:  G Ghaddar; A F Ruchon; M Carpentier; M Marcinkiewicz; N G Seidah; P Crine; L Desgroseillers; G Boileau
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

2.  Cloning and characterization of Aplysia neutral endopeptidase, a metallo-endopeptidase involved in the extracellular metabolism of neuropeptides in Aplysia californica.

Authors:  J P Zappulla; L Wickham; W Bawab; X F Yang; M V Storozhuk; V F Castellucci; L DesGroseillers
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

3.  In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes.

Authors:  Yinxing Liu; Hanjun Guan; Tina L Beckett; Maria Aparecida Juliano; Luiz Juliano; Eun Suk Song; K Martin Chow; M Paul Murphy; Louis B Hersh
Journal:  Peptides       Date:  2007-09-29       Impact factor: 3.750

4.  Neutral endopeptidase-24.11 (enkephalinase). Biosynthesis and localization in human fibroblasts.

Authors:  G Lorkowski; J E Zijderhand-Bleekemolen; E G Erdös; K von Figura; A Hasilik
Journal:  Biochem J       Date:  1987-12-01       Impact factor: 3.857

5.  A highly sensitive E.L.I.S.A. for endopeptidase-24.11, the common acute-lymphoblastic-leukaemia antigen (CALLA, CD-10), applicable to material of porcine and human origin.

Authors:  S Howell; H Murray; C S Scott; A J Turner; A J Kenny
Journal:  Biochem J       Date:  1991-09-01       Impact factor: 3.857

Review 6.  Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers.

Authors:  Xiaonan Zhang; Stig Linder; Martina Bazzaro
Journal:  Cancers (Basel)       Date:  2020-04-07       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.